Developer docs
API playgroundTry for free, no card

Search company profiles

Reveal-Dx

Full company profile

uuid0002hkx

Namestring
Reveal-Dx
Legal namestring
Reveal DX
Websiteurl
reveal-dx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Reveal-Dx is a Seattle-based private software company that develops RevealAI-Lung, an AI-powered computer-aided diagnosis (CADx) software for characterizing lung nodules detected on chest CT scans. The product generates a proprietary Malignancy Similarity Index (mSI) score from 3D lesion analysis using ensemble classification techniques and radiomic features, with results computed in seconds via single-click operation that integrates directly into radiologist PACS workflows. The software is the first AI-powered lung nodule CADx to achieve FDA 510(k) clearance (February 2026), MDR certification in the EU (November 2025), TGA clearance in Australia (September 2022), and Health Canada approval, and is the first Medical Imaging AI software to secure Medicare reimbursement in the US at $650 per scan under codes 0721T and 0722T.

The company operates a usage-based revenue model monetized through per-scan reimbursement and software licensing, distributed via a multi-channel strategy combining direct sales with regional exclusive partners: Sirona Medical (US), contextflow (EU), Riverain Technologies (Canada), Volpara Health (Australia/New Zealand), and Azra AI (oncology workflow integration). End customers are radiology departments, imaging centers, and lung cancer screening programs at hospitals and health systems. Clinical validation on over 1,500 patients demonstrated reduction in delayed cancer diagnoses from 45% to 25% at Royal United Hospitals Bath NHS Foundation Trust.

Reveal-Dx was formed in 2021 when Precision Medical Ventures acquired substantially all assets of Mindshare Medical and rebranded the entity, with Chris Wood appointed as CEO. The company has raised $4.25 million in a July 2024 funding round plus a $250,000 convertible note from Volpara Health, and holds U.S. Patent No. 10,255,997 covering the core mSI technology. The team is small (1-10 employees) and operates with a lean structure leveraging its distribution partner network for global commercialization across the US, EU, UK, Canada, Australia, and New Zealand.

Short descriptiontext

Reveal-Dx develops RevealAI-Lung, an FDA-cleared AI-powered CADx software that analyzes chest CT scans to characterize lung nodules via its proprietary Malignancy Similarity Index, serving radiology departments and lung cancer screening programs at hospitals and health systems globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI medical imaging, lung nodule analysis, radiology CADx software, cancer decision support, clinical decision support
Industry4 codes
PRIMARYHLAKANAI
Lung Cancer Screening & Pulmonary Nodule Clinic
SECONDARYHLACALAC
Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code2 codes
  • Medical and Diagnostic Laboratories62151
  • Diagnostic Imaging Centers621512
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
AI-Powered Radiology Clinical Decision Support Software
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Per-scan/software licensing
TypeUsage Based
Description

Medicare reimbursement at $650 per scan under codes 0721T and 0722T. Software can be purchased directly from RevealDx or through distributors (Sirona in US). Revenue generated per usage/scan basis as healthcare facilities use the software for lung nodule assessment.

medicaldevice-network.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Per-scan usage model reimbursable under Medicare
ModelUsage-basedBilling cadencePay-as-you-go
Notes

$650 per scan under Medicare Outpatient Prospective Payment System (OPPS) using codes 0721T and 0722T

medicaldevice-network.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

RevealDx develops RevealAI-Lung, an AI-powered Computer-Aided Diagnosis (CADx) software that analyzes chest CT scans to characterize lung nodules and generates a Malignancy Similarity Index (mSI) score to help radiologists assess malignancy risk and recommend appropriate follow-up. The product integrates directly into existing PACS systems, requires only a single click to operate, and returns results within seconds for use in lung cancer screening and incidental nodule management workflows. The software is FDA 510(k) cleared, CE Marked under MDR, TGA cleared, Health Canada approved, and reimbursable under Medicare codes 0721T and 0722T at $650 per scan.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduced delayed cancer diagnoses from 45% to 25% in retrospective study at Royal United Hospitals Bath NHS Foundation Trust
+3 more records
Product overview1 text field

Reveal-Dx is a single-product company offering RevealAI-Lung, the world's first CADx (Computer-Aided Diagnosis) software for lung nodule characterization. The product uses radiomics and AI to analyze chest CT scans and generates a proprietary Malignancy Similarity Index (mSI) score. RevealAI-Lung is available through multiple integrated distribution channels including PACS vendors (Fuji, Riverain), workflow platforms (Sirona, contextflow), and strategic distributors (Volpara Health, Azra AI). The software is reimbursable under Medicare codes 0721T and 0722T at $650 per scan.

Product and service1 record
1RevealAI-Lung
CategoryAI-Powered Radiology Clinical Decision Support Software
Description

AI-powered Computer-Aided Diagnosis (CADx) software that analyzes chest CT scans to characterize incidentally or screen-detected lung nodules and generate a Malignancy Similarity Index (mSI) score, helping radiologists assess malignancy risk and select appropriate follow-up. Integrates directly into existing PACS systems with single-click operation and returns results within seconds. FDA 510(k) cleared, CE Marked under MDR, TGA cleared, Health Canada approved, and reimbursable under Medicare codes 0721T and 0722T at $650 per scan. Validated on more than 1,500 patients, reducing delayed cancer diagnoses from 45% to 25% and lowering unnecessary invasive procedures. Targeted at hospital systems, academic medical centers, and outpatient imaging networks.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-14
Description

Integration of RevealAI-Lung's mSI score into Azra AI's enterprise oncology workflow platform for incidental findings and cancer care coordination. Builds on Azra AI's acquisition of Thynk health.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-03
Description

Product integration partnership. Riverain's ClearRead CT technology detects pulmonary nodules and provides volumetric data, then RevealDx's mSI characterizes malignancy risk. Riverain also distributes in Canada.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-11-17
Description

Comprehensive distribution and collaboration partnership for US market. Sirona integrates RevealAI-Lung with their cloud-native radiology workflow software and automated lung nodule measurement tools.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-08-03
Description

Exclusive distribution partnership for RevealDx products in the European Union and selected territories. contextflow integrates RevealAI-Lung into their SEARCH Lung CT platform, strengthening lung cancer screening capabilities with nodule characterization.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-09-20
Description

Strategic partnership for Australia and New Zealand distribution. Volpara received exclusive rights to sell RevealAI-Lung in Australia/New Zealand and non-exclusive rights for US market. Volpara invested US$250,000 via convertible note.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Optellum develops AI for lung cancer prediction and lung nodule management on chest CT, including FDA-cleared Lung Cancer Prediction (Virtual Nodule Clinic). It is the closest direct competitor to RevealAI-Lung, serving the same radiology and lung cancer screening use cases.

TypeDirect peer
Description

contextflow offers the SEARCH Lung CT clinical decision support platform for nodule characterization on chest CT. It is also Reveal-Dx's exclusive EU distributor, making it both a direct competitor and a channel partner with overlapping lung nodule AI capabilities.

TypeDirect peer
Description

Riverain's ClearRead CT detects and characterizes pulmonary nodules and competes head-to-head with RevealAI-Lung on chest CT. It is also Reveal-Dx's integration partner and Canadian distributor, combining competitive overlap with channel partnership.

TypeBroad incumbent
Description

Volpara Health is a broader breast and lung cancer screening software platform that distributes RevealAI-Lung in Australia and New Zealand. It offers adjacent lung screening capabilities and is a peer in the lung cancer screening workflow category.

TypeBroad incumbent
Description

Aidoc is a leading AI radiology platform offering a suite of FDA-cleared triage and workflow algorithms across multiple anatomies including chest CT. It competes for the same enterprise radiology AI budget and PACS integration footprint as Reveal-Dx.

TypeEmerging player
Description

Annalise.ai provides comprehensive AI decision support for chest X-ray and CT, including lung pathology detection. It is an emerging competitor in chest imaging AI with overlapping clinical use cases for radiologists and lung screening programs.

TypeEmerging player
Description

Qure.ai develops deep learning models for chest X-ray and CT interpretation including lung nodule and tuberculosis detection. It is an emerging global player with overlapping chest imaging AI applications and similar international regulatory expansion.

TypeOthers
Description

Sirona Medical is a cloud-native radiology workflow platform and Reveal-Dx's exclusive US distributor for RevealAI-Lung. While it can embed competing AI tools, its primary role is as a distribution and integration partner rather than a direct nodule AI competitor.

TypeOthers
Description

Azra AI is an enterprise platform for incidental findings and oncology workflow automation that integrates RevealAI-Lung's mSI score. It is an adjacent ecosystem partner addressing oncology care coordination that complements Reveal-Dx's diagnostic capability.

TypeBroad incumbent
Description

iCAD offers AI-powered cancer detection and workflow solutions including ProFound AI for breast and ProFound AI Risk, with adjacent imaging AI capabilities. It is a broader incumbent in imaging AI with some overlap in cancer characterization workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Reveal-Dx

AI-Powered Radiology Clinical Decision Support Softwarereveal-dx.com

Reveal-Dx develops RevealAI-Lung, an FDA-cleared AI-powered CADx software that analyzes chest CT scans to characterize lung nodules via its proprietary Malignancy Similarity Index, serving radiology departments and lung cancer screening programs at hospitals and health systems globally.

What Reveal-Dx does

Reveal-Dx is a Seattle-based private software company that develops RevealAI-Lung, an AI-powered computer-aided diagnosis (CADx) software for characterizing lung nodules detected on chest CT scans. The product generates a proprietary Malignancy Similarity Index (mSI) score from 3D lesion analysis using ensemble classification techniques and radiomic features, with results computed in seconds via single-click operation that integrates directly into radiologist PACS workflows. The software is the first AI-powered lung nodule CADx to achieve FDA 510(k) clearance (February 2026), MDR certification in the EU (November 2025), TGA clearance in Australia (September 2022), and Health Canada approval, and is the first Medical Imaging AI software to secure Medicare reimbursement in the US at $650 per scan under codes 0721T and 0722T.

The company operates a usage-based revenue model monetized through per-scan reimbursement and software licensing, distributed via a multi-channel strategy combining direct sales with regional exclusive partners: Sirona Medical (US), contextflow (EU), Riverain Technologies (Canada), Volpara Health (Australia/New Zealand), and Azra AI (oncology workflow integration). End customers are radiology departments, imaging centers, and lung cancer screening programs at hospitals and health systems. Clinical validation on over 1,500 patients demonstrated reduction in delayed cancer diagnoses from 45% to 25% at Royal United Hospitals Bath NHS Foundation Trust.

Reveal-Dx was formed in 2021 when Precision Medical Ventures acquired substantially all assets of Mindshare Medical and rebranded the entity, with Chris Wood appointed as CEO. The company has raised $4.25 million in a July 2024 funding round plus a $250,000 convertible note from Volpara Health, and holds U.S. Patent No. 10,255,997 covering the core mSI technology. The team is small (1-10 employees) and operates with a lean structure leveraging its distribution partner network for global commercialization across the US, EU, UK, Canada, Australia, and New Zealand.

Reveal-Dx firmographics

Firmographics
Name
Reveal-Dx
Legal name
Reveal DX
Website
https://reveal-dx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Reveal-Dx develops RevealAI-Lung, an FDA-cleared AI-powered CADx software that analyzes chest CT scans to characterize lung nodules via its proprietary Malignancy Similarity Index, serving radiology departments and lung cancer screening programs at hospitals and health systems globally.
Ownership category
akta.pro rank

Reveal-Dx industry classification

Industry
Product category
AI-Powered Radiology Clinical Decision Support Software
NAICS
Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAKANAI
Lung Cancer Screening & Pulmonary Nodule Clinic
SECONDARYHLACALAC
Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLACABAM
Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • AI medical imaging
  • Lung nodule analysis
  • Radiology CADx software
  • Cancer decision support
  • Clinical decision support

Where Reveal-Dx is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Reveal-Dx business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Per-scan/software licensing: Medicare reimbursement at $650 per scan under codes 0721T and 0722T. Software can be purchased directly from RevealDx or through distributors (Sirona in US). Revenue generated per usage/scan basis as healthcare facilities use the software for lung nodule assessment.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goPer-scan usage model reimbursable under Medicare

Go-to-market motion2 records

Distribution channels6 records

Marketing channels6 records

Reveal-Dx product offering

Product offering

Core offering

RevealDx develops RevealAI-Lung, an AI-powered Computer-Aided Diagnosis (CADx) software that analyzes chest CT scans to characterize lung nodules and generates a Malignancy Similarity Index (mSI) score to help radiologists assess malignancy risk and recommend appropriate follow-up. The product integrates directly into existing PACS systems, requires only a single click to operate, and returns results within seconds for use in lung cancer screening and incidental nodule management workflows. The software is FDA 510(k) cleared, CE Marked under MDR, TGA cleared, Health Canada approved, and reimbursable under Medicare codes 0721T and 0722T at $650 per scan.

Product overview

Reveal-Dx is a single-product company offering RevealAI-Lung, the world's first CADx (Computer-Aided Diagnosis) software for lung nodule characterization. The product uses radiomics and AI to analyze chest CT scans and generates a proprietary Malignancy Similarity Index (mSI) score. RevealAI-Lung is available through multiple integrated distribution channels including PACS vendors (Fuji, Riverain), workflow platforms (Sirona, contextflow), and strategic distributors (Volpara Health, Azra AI). The software is reimbursable under Medicare codes 0721T and 0722T at $650 per scan.

Differentiator

Problem solved

Functional benefit

Products and services

  • RevealAI-Lung AI-powered Computer-Aided Diagnosis (CADx) software that analyzes chest CT scans to characterize incidentally or screen-detected lung nodules and generate a Malignancy Similarity Index (mSI) score, helping radiologists assess malignancy risk and select appropriate follow-up. Integrates directly into existing PACS systems with single-click operation and returns results within seconds. FDA 510(k) cleared, CE Marked under MDR, TGA cleared, Health Canada approved, and reimbursable under Medicare codes 0721T and 0722T at $650 per scan. Validated on more than 1,500 patients, reducing delayed cancer diagnoses from 45% to 25% and lowering unnecessary invasive procedures. Targeted at hospital systems, academic medical centers, and outpatient imaging networks.

Quantifiable outcome

  • Reduced delayed cancer diagnoses from 45% to 25% in retrospective study at Royal United Hospitals Bath NHS Foundation Trust
  • +3 more outcomes

Companies that use Reveal-Dx

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Reveal-Dx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability3 records

Feature4 records

Reveal-Dx partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Azra AIcoreTechnology or Integration · 14 May 2026Integration of RevealAI-Lung's mSI score into Azra AI's enterprise oncology workflow platform for incidental findings and cancer care coordination. Builds on Azra AI's acquisition of Thynk health.
  • Riverain TechnologiescoreTechnology or Integration · 3 October 2024Product integration partnership. Riverain's ClearRead CT technology detects pulmonary nodules and provides volumetric data, then RevealDx's mSI characterizes malignancy risk. Riverain also distributes in Canada.
  • Sirona MedicalcoreChannel Partner/ Reseller/ Distributor · 17 November 2022Comprehensive distribution and collaboration partnership for US market. Sirona integrates RevealAI-Lung with their cloud-native radiology workflow software and automated lung nodule measurement tools.
  • contextflowcoreChannel Partner/ Reseller/ Distributor · 3 August 2022Exclusive distribution partnership for RevealDx products in the European Union and selected territories. contextflow integrates RevealAI-Lung into their SEARCH Lung CT platform, strengthening lung cancer screening capabilities with nodule characterization.
  • Volpara HealthcoreChannel Partner/ Reseller/ Distributor · 20 September 2021Strategic partnership for Australia and New Zealand distribution. Volpara received exclusive rights to sell RevealAI-Lung in Australia/New Zealand and non-exclusive rights for US market. Volpara invested US$250,000 via convertible note.

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Reveal-Dx competitors and assessment

Company assessment

Direct peers

  • Optellum: Optellum develops AI for lung cancer prediction and lung nodule management on chest CT, including FDA-cleared Lung Cancer Prediction (Virtual Nodule Clinic). It is the closest direct competitor to RevealAI-Lung, serving the same radiology and lung cancer screening use cases.
  • contextflow: contextflow offers the SEARCH Lung CT clinical decision support platform for nodule characterization on chest CT. It is also Reveal-Dx's exclusive EU distributor, making it both a direct competitor and a channel partner with overlapping lung nodule AI capabilities.
  • Riverain Technologies: Riverain's ClearRead CT detects and characterizes pulmonary nodules and competes head-to-head with RevealAI-Lung on chest CT. It is also Reveal-Dx's integration partner and Canadian distributor, combining competitive overlap with channel partnership.

Broad incumbents

  • Volpara Health: Volpara Health is a broader breast and lung cancer screening software platform that distributes RevealAI-Lung in Australia and New Zealand. It offers adjacent lung screening capabilities and is a peer in the lung cancer screening workflow category.
  • Aidoc: Aidoc is a leading AI radiology platform offering a suite of FDA-cleared triage and workflow algorithms across multiple anatomies including chest CT. It competes for the same enterprise radiology AI budget and PACS integration footprint as Reveal-Dx.
  • iCAD: iCAD offers AI-powered cancer detection and workflow solutions including ProFound AI for breast and ProFound AI Risk, with adjacent imaging AI capabilities. It is a broader incumbent in imaging AI with some overlap in cancer characterization workflows.

Emerging players

  • Annalise.ai: Annalise.ai provides comprehensive AI decision support for chest X-ray and CT, including lung pathology detection. It is an emerging competitor in chest imaging AI with overlapping clinical use cases for radiologists and lung screening programs.
  • Qure.ai: Qure.ai develops deep learning models for chest X-ray and CT interpretation including lung nodule and tuberculosis detection. It is an emerging global player with overlapping chest imaging AI applications and similar international regulatory expansion.

Others

  • Sirona Medical: Sirona Medical is a cloud-native radiology workflow platform and Reveal-Dx's exclusive US distributor for RevealAI-Lung. While it can embed competing AI tools, its primary role is as a distribution and integration partner rather than a direct nodule AI competitor.
  • Azra AI: Azra AI is an enterprise platform for incidental findings and oncology workflow automation that integrates RevealAI-Lung's mSI score. It is an adjacent ecosystem partner addressing oncology care coordination that complements Reveal-Dx's diagnostic capability.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Reveal-Dx compliance and trust

Trust signal

Compliance4 records

Reveal-Dx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Reveal-Dx leadership team

Management profile

Number of profiles

Profiles7 records

Reveal-Dx funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Reveal-Dx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reveal-Dx

What does Reveal-Dx do?

RevealDx develops RevealAI-Lung, an AI-powered Computer-Aided Diagnosis (CADx) software that analyzes chest CT scans to characterize lung nodules and generates a Malignancy Similarity Index (mSI) score to help radiologists assess malignancy risk and recommend appropriate follow-up. The product integrates directly into existing PACS systems, requires only a single click to operate, and returns results within seconds for use in lung cancer screening and incidental nodule management workflows. The software is FDA 510(k) cleared, CE Marked under MDR, TGA cleared, Health Canada approved, and reimbursable under Medicare codes 0721T and 0722T at $650 per scan.

Is Reveal-Dx a public or private company?

Reveal-Dx is a private company. It is classified as private equity controlled and is currently operating.

When was Reveal-Dx founded?

Reveal-Dx was founded in 2021. It employs 11 to 50 people.

Where is Reveal-Dx based?

Reveal-Dx is headquartered in Seattle, United States, in the North America region.

How does Reveal-Dx make money?

One revenue line is on record: per-scan/software licensing.

Who are Reveal-Dx's main competitors?

Direct peers on record are Optellum, contextflow and Riverain Technologies. Broad incumbents are Volpara Health, Aidoc and iCAD. Emerging players are Annalise.ai and Qure.ai. Others are Sirona Medical and Azra AI.

Does Reveal-Dx have an API?

No public API is recorded for Reveal-Dx.

What industry is Reveal-Dx in?

Reveal-Dx's product category is AI-Powered Radiology Clinical Decision Support Software. Its primary akta.pro industry code is HLAKANAI, Lung Cancer Screening & Pulmonary Nodule Clinic, with a secondary code of HLACALAC, Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories. Its NAICS code is 62151 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Med-Tech InsightsRevealDx announces distribution agreement and investment from 4DMedicalRevealDx announced a distribution agreement and $3.4 million investment from 4DMedical, expanding access to its RevealAI-Lung product. The software, validated on over 1,500 patients, has received MDR, TGA, and FDA clearance. 4DMedical's acquisition of contextflow integrates RevealAI-Lung into its platform.FinSMEsRevealDx Received $3.4M Investment From 4DMedicalRevealDx, a Seattle-based lung nodule AI provider, received a $3.4M investment from 4DMedical. The company will use the funds to expand access to its RevealAI-Lung product, which characterizes lung nodules with a malignancy similarity index. RevealDx holds FDA clearance and operates in Europe and the U.S.NewsbizkootCrompton & Greaves Q1 Results: Profit, Revenue & GrowthRevealDx announced a distribution partnership and $3.4 million strategic investment from 4DMedical to broaden availability of its RevealAI-Lung AI lung nodule analysis platform. The deal follows 4DMedical's acquisition of contextflow, and the platform holds MDR, TGA, and FDA clearances.AI InsiderRevealDx Announces Distribution Agreement And Investment From 4DMedicalRevealDx announced a $3.4 million strategic investment and distribution agreement with 4DMedical to expand access to its AI-powered RevealAI-Lung lung nodule assessment software. The FDA-cleared, MDR-certified, and TGA-approved software has been integrated into 4DMedical's contextflow platform and is already used at several European clinical sites. It is validated on over 1,500 patients and eligible for Medicare reimbursement in the U.S.Reveal-DxRevealDx Announces Distribution Agreement and Investment from 4DMedicalRevealDx announced a distribution agreement and $3.4 million investment from 4DMedical to expand access to its RevealAI-Lung lung nodule AI software. The product has received MDR certification, TGA approval, and FDA clearance, and is reimbursable by Medicare. The partnership aims to integrate the technology into 4DMedical's contextflow platform.Radiology BusinessNew partnership seeks to streamline AI integration into lung cancer screeningSirona Medical and RevealDX have formed a partnership to integrate AI tools for lung cancer screening, combining Sirona's Workspace platform with RevealDX's RevealAI-Lung software. This integration aims to streamline radiologist workflows by embedding decision support directly into existing PACS and RIS systems without requiring major IT overhauls.Pulse 2.0RevealDx: Interview With CEO And Chair Chris Wood About The Lung Cancer Improvement CompanyRevealDx, a Seattle-based software company, is developing an AI-enabled lung cancer decision-support tool called RevealAI-Lung that provides a Malignancy Similarity Index to assist radiologists in diagnosing lung nodules. CEO Chris Wood states that the technology has demonstrated superior performance compared to current guidelines in studies published by the Journal of the American College of Radiology. The company aims to secure FDA clearance to expand its operations into a US market estimated at over $2 billion, with plans for further institutional funding following regulatory approval.GeekWireSeattle startup RevealDx lands $4.2M to help clinicians diagnose lung cancerSeattle-based startup RevealDx has raised $4.25 million in a new investment round to support its machine learning software for lung cancer diagnosis. The company, formerly known as Mindshare Medical, currently serves four customers in Europe and is working toward FDA approval in the United States.PR NewswireSirona Selects Koios, Rad.ai, & RevealDX as Founding AI Partners Ahead of November Launch EventSirona Medical announced expanded partnerships with Koios, Rad.ai, and RevealDX ahead of its November 13 launch event. The company will serve as an official reseller for all three vendors and prepare its Amplify SDK for public release, establishing the first open developer ecosystem in clinical radiology.PR NewswireSirona Medical partners with RevealDX to transform lung cancer screening with a comprehensive suite of reimbursed AI tools.Sirona Medical announced a partnership with RevealDX and integrated Nines' FDA-cleared automated measurement tool to improve lung nodule assessment. The collaboration aims to enhance diagnostic quality for lung cancer, the leading cause of cancer-related death in the United States.